Knowledge-based approaches in the design and selection of compound libraries for drug discovery

Vellarkad N. Viswanadhan, Chenera Balan, Christopher Hulme, Janet C. Cheetham, Yaxiong Sun

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

In the past decade, the pharmaceutical industry has realized the increasing significance of impacting the early phase hit-to-lead development in the drug discovery process. In particular, knowledge-based approaches emerged and evolved to address a multitude of issues such as absorption, distribution, metabolism and excretion (ADME), potency, toxicity and overall drugability. Each of these approaches seeks to bring together all relevant pieces of information and create a knowledge-oriented process to deploy such information in drug discovery. This review focuses on work relating to drugability, which aims at obtaining hits (or leads) that have enhanced likelihoods of leading to successful clinical candidates by medicinal chemistry efforts. The period covered in this review is from 1997 (since the publication of Lipinski's rule of 5) to March 2002.

Original languageEnglish (US)
Pages (from-to)400-406
Number of pages7
JournalCurrent Opinion in Drug Discovery and Development
Volume5
Issue number3
StatePublished - May 2002
Externally publishedYes

Fingerprint

Drug Discovery
Libraries
Pharmaceutical Chemistry
Drug Industry
Publications
Lead

Keywords

  • ADME
  • Drug properties
  • Drug-likeness
  • Drugability
  • Knowledge-based approaches
  • Library design
  • Oral absorption

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Knowledge-based approaches in the design and selection of compound libraries for drug discovery. / Viswanadhan, Vellarkad N.; Balan, Chenera; Hulme, Christopher; Cheetham, Janet C.; Sun, Yaxiong.

In: Current Opinion in Drug Discovery and Development, Vol. 5, No. 3, 05.2002, p. 400-406.

Research output: Contribution to journalArticle

Viswanadhan, Vellarkad N. ; Balan, Chenera ; Hulme, Christopher ; Cheetham, Janet C. ; Sun, Yaxiong. / Knowledge-based approaches in the design and selection of compound libraries for drug discovery. In: Current Opinion in Drug Discovery and Development. 2002 ; Vol. 5, No. 3. pp. 400-406.
@article{93941bdba82c4b2b82c2c24c71a0d1ee,
title = "Knowledge-based approaches in the design and selection of compound libraries for drug discovery",
abstract = "In the past decade, the pharmaceutical industry has realized the increasing significance of impacting the early phase hit-to-lead development in the drug discovery process. In particular, knowledge-based approaches emerged and evolved to address a multitude of issues such as absorption, distribution, metabolism and excretion (ADME), potency, toxicity and overall drugability. Each of these approaches seeks to bring together all relevant pieces of information and create a knowledge-oriented process to deploy such information in drug discovery. This review focuses on work relating to drugability, which aims at obtaining hits (or leads) that have enhanced likelihoods of leading to successful clinical candidates by medicinal chemistry efforts. The period covered in this review is from 1997 (since the publication of Lipinski's rule of 5) to March 2002.",
keywords = "ADME, Drug properties, Drug-likeness, Drugability, Knowledge-based approaches, Library design, Oral absorption",
author = "Viswanadhan, {Vellarkad N.} and Chenera Balan and Christopher Hulme and Cheetham, {Janet C.} and Yaxiong Sun",
year = "2002",
month = "5",
language = "English (US)",
volume = "5",
pages = "400--406",
journal = "Current Opinion in Drug Discovery and Development",
issn = "1367-6733",
publisher = "Current Drugs Ltd.",
number = "3",

}

TY - JOUR

T1 - Knowledge-based approaches in the design and selection of compound libraries for drug discovery

AU - Viswanadhan, Vellarkad N.

AU - Balan, Chenera

AU - Hulme, Christopher

AU - Cheetham, Janet C.

AU - Sun, Yaxiong

PY - 2002/5

Y1 - 2002/5

N2 - In the past decade, the pharmaceutical industry has realized the increasing significance of impacting the early phase hit-to-lead development in the drug discovery process. In particular, knowledge-based approaches emerged and evolved to address a multitude of issues such as absorption, distribution, metabolism and excretion (ADME), potency, toxicity and overall drugability. Each of these approaches seeks to bring together all relevant pieces of information and create a knowledge-oriented process to deploy such information in drug discovery. This review focuses on work relating to drugability, which aims at obtaining hits (or leads) that have enhanced likelihoods of leading to successful clinical candidates by medicinal chemistry efforts. The period covered in this review is from 1997 (since the publication of Lipinski's rule of 5) to March 2002.

AB - In the past decade, the pharmaceutical industry has realized the increasing significance of impacting the early phase hit-to-lead development in the drug discovery process. In particular, knowledge-based approaches emerged and evolved to address a multitude of issues such as absorption, distribution, metabolism and excretion (ADME), potency, toxicity and overall drugability. Each of these approaches seeks to bring together all relevant pieces of information and create a knowledge-oriented process to deploy such information in drug discovery. This review focuses on work relating to drugability, which aims at obtaining hits (or leads) that have enhanced likelihoods of leading to successful clinical candidates by medicinal chemistry efforts. The period covered in this review is from 1997 (since the publication of Lipinski's rule of 5) to March 2002.

KW - ADME

KW - Drug properties

KW - Drug-likeness

KW - Drugability

KW - Knowledge-based approaches

KW - Library design

KW - Oral absorption

UR - http://www.scopus.com/inward/record.url?scp=0036589827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036589827&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 400

EP - 406

JO - Current Opinion in Drug Discovery and Development

JF - Current Opinion in Drug Discovery and Development

SN - 1367-6733

IS - 3

ER -